

MPNs and GVHD

		Clinical Proof of Concept	Pivotal	Approved
Jakafi® (ruxolitinib) ¹ JAK1/JAK2	Myelofibrosis ² , polycythemia vera ² , GVHD ²			
Niktimvo™ (axatilimab-csfr) ³ CSF-1R	3L+ chronic GVHD ²			
ruxolitinib XR (QD) JAK1/JAK2	Bioequivalence and stability testing			
axatilimab ³ CSF-1R	1L chronic GVHD + ruxolitinib			
zilurgisertib ALK2	Myelofibrosis-associated anemia ± ruxolitinib			
INCB057643 BET	Myelofibrosis ± ruxolitinib			
INCA033989 mutCALR	Myelofibrosis or ET with CALR mutation ± ruxolitinib			
INCB160058 JAK2 ^{V617F}	JAK2 ^{V617F} -mutated myelofibrosis			

Dermatology and Other IAI

Opzelura® (ruxolitinib) cream JAK1/JAK2	AD ² , vitiligo ^{2,4}			
ruxolitinib cream JAK1/JAK2	Pediatric AD, prurigo nodularis, pediatric vitiligo			
	Hidradenitis suppurativa, lichen planus, lichen sclerosus			
povorcitinib JAK1	Hidradenitis suppurativa, vitiligo, prurigo nodularis			
	CSU, asthma			
INCB000262 (EP262) MRGPRX2	CSU, chronic inducible urticaria, AD			
INCB000547 (EP547) MRGPRX4	Cholestatic pruritus			
zilurgisertib ALK2	Fibrodysplasia ossificans progressiva			

General Hematology/Oncology

		Clinical Proof of Concept	Pivotal	Approved
Pemazyre® (pemigatinib) FGFR1/2/3	2L+ cholangiocarcinoma ⁵ , MLNs with <i>FGFR1</i> rearrangement ^{2,6}			
Monjuvi® (tafasitamab-cxix) Minjuvi® (tafasitamab) CD19	r/r DLBCL ^{2,4,7}			
Iclusig® (ponatinib) ⁸ BCR-ABL	Chronic myeloid leukemia ⁴ , Ph+ ALL ⁴			
Zynyz® (retifanlimab-dlwr) ⁹ Zynyz® (retifanlimab) ⁹ PD-1	Merkel cell carcinoma ^{2,4}			
tafasitamab CD19	r/r follicular lymphoma, r/r MZL, 1L DLBCL			
retifanlimab ⁹ PD-1 (mAb)	Squamous cell anal carcinoma, NSCLC			
	MSI-H endometrial cancer			
itacitinib JAK1	Cytokine release syndrome			
INCB123667 CDK2	Solid tumors			
INCA33890 ¹⁰ TGFBR2×PD-1	Solid tumors			
INCB161734 KRAS ^{G12D}	KRAS ^{G12D} -mutated solid tumors			

Partnered Programs

Olumiant® (baricitinib) ¹¹ JAK1/JAK2	Rheumatoid arthritis ¹² , COVID-19 ¹² , AD ^{4,6} , alopecia areata ^{2,4,6}			
Tabrecta® (capmatinib) ¹³ MET	NSCLC with METex14 ¹²			
axatilimab ³ CSF-1R	Idiopathic pulmonary fibrosis ¹⁴			

17

Molecular Targets

21

Clinical Compounds

9

Approved Products

Updated as of August 27, 2024

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners.

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in Europe 5. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 6. Approved in Japan 7. Approved in Canada 8. European rights to Iclusig licensed from Takeda 9. Licensed from MacroGenics 10. Development in collaboration with Merus 11. Worldwide rights to baricitinib licensed to Lilly 12. Approved in multiple territories globally 13. Worldwide rights to capmatinib licensed to Novartis 14. IPF study currently led and funded by Syndax

1L, first-line; 2L+, second-line or later; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; CSU, chronic spontaneous urticaria; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocytopenia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; IPF, idiopathic pulmonary fibrosis; mAb, monoclonal antibody; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; mut, mutant; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.